Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Biologics for chronic inflammatory skin diseases: an update for the clinician

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Systematic review of machine learning for diagnosis and prognosis in dermatology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Combined treatment with omalizumab and etanercept in a patient with chronic spontaneous urticaria and rheumatoid arthritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Caring for young people with moderate to severe psoriasis: an interpretive description of parental perspectives

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Risk of systemic infections in adults with atopic dermatitis: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Treatment of adult atopic dermatitis patients according to disease characteristics and demographics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jonathan Barker
  • Giampiero Girolomoni
  • Alexander Egeberg
  • Joao Goncalves
  • Burkhard Pieper
  • Taegyun Kang
Vis graf over relationer

Tumor necrosis factor (TNF) inhibitors account for a large proportion of drugs used to treat psoriasis and are indicated first-line options in certain settings. Several biosimilar drugs based on the anti-TNF agents adalimumab, infliximab, and etanercept are now available for use in patients with psoriasis. The favorable cost differential of biosimilars is expected to improve access to biologic therapy for biologic-naive psoriasis patients, who are often undertreated. Also, substantial cost savings can be made if patients are switched to biosimilars. To date, most clinical testing of anti-TNF biosimilars approved for use in psoriasis has been performed in patients with rheumatoid arthritis, and the results extrapolated to psoriasis. Although this may initially raise concerns for clinicians looking to start their psoriasis patients on biologic treatment with a biosimilar or switch from an original biologic to a biosimilar, the process of extrapolation is tightly regulated and scientifically justified. Furthermore, available real-world evidence of the safety and efficacy of anti-TNF agents in patients with psoriasis complements clinical trial data in patients with rheumatoid arthritis. When equipped with the appropriate knowledge, clinicians should have confidence to use biosimilars for the treatment of psoriasis.

OriginalsprogEngelsk
TidsskriftThe Journal of dermatological treatment
Vol/bind31
Udgave nummer8
Sider (fra-til)794-800
Antal sider7
ISSN0954-6634
DOI
StatusUdgivet - dec. 2020

ID: 61201951